COSMO Pharmaceuticals N.V. (CH:COPN)
:COPN
Want to see CH:COPN full AI Analyst Report?
COPN Stock Chart & Stats
CHF97.80
-CHF3.50(-5.38%)
At close: 4:00 PM EST
CHF97.80
-CHF3.50(-5.38%)
Day’s Range― - ―
52-Week RangeCHF53.40 - CHF129.40
Previous CloseN/A
Volume25.75K
Average Volume (3M)19.52K
Market Cap
CHF1.23B
Enterprise ValueCHF1.33B
Total Cash (Recent Filing)CHF122.66M
Total Debt (Recent Filing)CHF4.26M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Jul 20, 2026Next Dividend Ex-DateN/A
Dividend Yield1.82%
Share Statistics
EPS (TTM)-0.23
Shares Outstanding17,543,522
10 Day Avg. Volume18,700
30 Day Avg. Volume19,520
Financial Highlights & Ratios
PEG Ratio4.83
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF143.33Price Target Upside46.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.1
Revenue Forecast (FY)CHF106.30M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and substantial equity provide durable financial flexibility: the company can absorb revenue swings, fund R&D or clinical programs, and maintain partnerships without immediate external financing. This reduces insolvency risk and preserves strategic optionality over months.
Specialized Gastroenterology FocusA concentrated product and customer focus in gastroenterology/endoscopy creates structural advantages: deep clinical relationships, repeatable device and therapy demand, and clearer R&D prioritization. That specialization supports durable commercial channels and licensing potential.
Ability To Generate Strong Cash In Good YearsThe company has demonstrated capacity to produce very strong operating and free cash flow in favorable periods, indicating the business model can be highly cash-generative when execution and market conditions align. This historic cash power underpins long-term funding and reinvestment potential.
Bears Say
Revenue And Earnings VolatilityLarge swings in revenue and earnings erode predictability and hinder long-term planning. Volatility complicates investment decisions, weakens bargaining power with partners, and increases the risk that one or two adverse quarters materially impair R&D and commercial programs over the next several months.
Recent Cash-flow DeteriorationA switch to negative operating and free cash flow in the latest year reduces self-funding capacity, forcing reliance on reserves or external capital. That raises execution risk for pipeline development, commercial investments, and dividends, and constrains flexibility in the 2–6 month horizon if trends persist.
Profitability Deterioration In 2025Margins swung negative, indicating underlying cost or revenue issues that may be structural. Sustained negative EBIT and net margins will deplete equity and limit reinvestment, undermining long-term competitiveness and partner confidence unless management restores margin durability.
COSMO Pharmaceuticals N.V. News
COPN FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was CHF53.40 and its highest was CHF129.40 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is CHF1.23B.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Jul 20, 2026 which is in 43 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Mar 09, 2026. The company reported -CHF0.092 earnings per share for the quarter, missing the consensus estimate of CHF0.183 by -CHF0.275.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. pays a Annually dividend of CHF1.926 which represents an annual dividend yield of 1.82%. See more information on COSMO Pharmaceuticals N.V. dividends here
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate is 0.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -CHF0.092 in its last earnings report, missing expectations of CHF0.183. Following the earnings report the stock price went down -10.522%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in CH:COPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
COPN Stock 12 Month Forecast
Average Price Target
CHF143.33
▲(46.56% Upside)
Technical Analysis
Options Prices
Currently, No data available
---